12 Aug 2026, 01:54 UTC253 viewsread 12 August 2026
핀테라퓨틱스, 'CK1α 분자접착제' AML 항암기전 "논문" TP53 야생형 AML서 효능, 정상 조혈모세포 독성 '최소화' 연구결과 Cancer Research 게재..'PIN-5018' 1상 4번째 코호트 용량평가 진행中 https://m.biospectator.com/view/news_view.php?varAtcId=29519
Channel
바이오스펙테이터
@biospectatorT
On this record: Growth · Engagement · What this channel posts · Posts · Citations · Cite this entry
5,878subscribers
-6 since we began measuring on 6 August 2026
Risers and fallers across the register · movement among entries of 3,162–10,000.
Register entry
| Telegram ID | -1001329038589 |
|---|---|
| Type | Channel |
| Username | @biospectatorT |
| Description | 국내 최초 바이오 전문언론사 '바이오스펙테이터'의 채널입니다. |
| Created | 3 May 2021 — measured — cross-checked against a third-party dataset (ext.tg_channel) |
| First recorded | 6 August 2026 |
| Last confirmed live | 10 August 2026 |
| Measurements held | 3 |
| Confirmed unchanged | 1 time, most recently 10 August 2026 |
| On Telegram | t.me/biospectatorT |
Growth
| Measured (UTC) | Subscribers | Change |
|---|---|---|
| 10 Aug 2026, 04:54 | 5,878 | -4 |
| 7 Aug 2026, 02:30 | 5,882 | -2 |
| 6 Aug 2026, 11:02 | 5,884 | first reading |
Engagement
51 posts held, back to 4 August 2026 — the reader has not yet reached the start of this channel’s public history, so older posts may sit further back, unread. Read across 9 pagesof Telegram’s post history, 20 posts per page.
- ERR · 30 days
- 14.7%
- avg views ÷ 5,878 subscribers
- Avg views / post
- 862
- 51 posts measured
- Reaction rate
- —
- this channel exposes no reaction counts
- Posts in window
- 51
- of 51 held
ERR is average views per post over the last 30 days divided by subscribers, the definition TGStat uses, so this figure is comparable with the one you will see elsewhere. It falls structurally as a channel grows: a high ERR on a small channel and a low one on a large channel describe reach mathematics, not quality. We publish the figure and the sample it came from and pass no verdict on it.
ER is defined industry-wide as (forwards + reactions + comments) ÷ views— note the denominator is views, not subscribers. Telegram’s public web preview carries views and reactions but not forward or comment counts, so the reaction rate above is the reactions term only and is therefore a floor: the true ER for this channel is higher by an amount we have not measured and will not estimate.
| Window | Rolling 30 days · latest post in window 12 August 2026 |
|---|---|
| Posts held | 51 (4 August 2026 – 12 August 2026) |
| Views total | 43,942 |
| Reactions total | — |
| Forwards / comments | not exposed by the public surface — not measured, not estimated |
| Readings taken | 12 Aug 2026, 03:46 UTC |
Views are a single reading per post, taken at the time above. A post published in the last day or two is still accumulating views, which pulls the 30-day average down slightly. That is a property of the standard definition rather than a fault in it, so we keep the definition rather than “correcting” the number into something nobody can reproduce.
Precision. Telegram publishes view counts on its public widget in short form — 8.12K, 3.7M — so any reading at or above 1,000 reaches us rounded to three significant figures, and only counts below 1,000 are exact. Averages and rates derived from them are shown to the same precision rather than to the unit: a figure like 3,701,250 would assert digits nobody measured.
Reaction counts are published per emoji and rounded the same way, so a total below 1,000 is exact and a larger one is a sum that may carry a rounded component from each emoji above 1,000. Because it is a sum, it does not look rounded — read a large reaction total as three significant figures per contributing emoji rather than as the figure it prints.
What this channel posts
- Photos
- ≈4
- Links
- ≈11,900
Lifetime counters from Telegram’s own channel header, read 12 August 2026 — not the date at the top of this page, which is when the subscriber count was last read. A count marked ≈ was rounded by Telegram before we ever saw it — t.me prints these counters in full below 1,000 and to three significant figures above, so ≈142,000 means somewhere between 141,500 and 142,499.
Recent posts
12 Aug 2026, 01:07 UTC309 viewsread 12 August 2026
시오나 테라퓨틱스(Sionna Therapeutics)의 NBD1 안정제(stabilizers) 후보물질 ‘SION-719’가 낭포성섬유증(cystic fibrosis, CF)을 적응증으로 하는 개념입증(PoC) 임상2a상에서 효능을 나타내지 못하며 실패했습니다. 이번 임상은 경쟁사 버텍스 파마슈티컬(Vertex Pharmaceuticals)의 CF 치료제 ‘트리카프타(Trikafta)’에 시오나의 리드에셋 SION-719를 추가하는 요법을 평가하는 것이었는데요. 이번 실패에 따라 시오나는 해당 요법에 대한 SION-719의 개발을 중단하게 됐으며, 향후 조치를 검토하는 동안 자본을 보존하기 위한 조치를 취할 예정이라고 설명했습니다. 이제 시오나가 진행중인 임상은 후속 NBD1 안정제 ‘SION-451’과 TMD1 조절제 ‘갈리카프터(ga…
11 Aug 2026, 23:56 UTC909 viewsread 12 August 2026
사일런스 테라퓨틱스(Silence Therapeutics)의 RNA간섭(RNAi) 약물이 희귀혈액암인 진성다혈구증(polycythemia vera, PV)을 적응증으로 하는 임상2상에서 1차종결점을 달성한 성공적인 결과를 나타냈네요. 현재 PV 적응증에서 가장 앞선 에셋은 다케다(Takeda)와 프로타고니스트(Protagonist)의 헵시딘 유사체 ‘러스퍼타이드(rusfertide)'입니다. 다케다는 지난 2024년 1월 계약금만 3억달러에 임상3상 단계의 러스퍼타이드를 사들인 바 있는데요. 러스퍼타이드는 미국 식품의약국(FDA)으로부터 승인신청이 접수된 상태로, 올해 3분기 중에 승인여부가 결정됩니다. 아직 경쟁 가능성은 있으며, 사일런스의 TMPRSS6 siRNA ‘디베시란(divesiran)’은 최대 연4회 피하주사(SC) 방식으로 …
11 Aug 2026, 22:01 UTC453 viewsread 12 August 2026
#바이오스펙테이터 #전일(8/11, TUE) #전체기사 ▶ 라이프마인, 2.63억弗 유치..장기이식 '新칼시뉴린 저해제' https://www.biospectator.com/news/view/29503 ▶ 타르수스, ‘희귀안질환’ 개발社 8억弗 인수.."망막 강화" https://www.biospectator.com/news/view/29504 ▶ SK바이오사이언스, 2Q 매출 1557억 "전년比 3.7%↓" https://www.biospectator.com/news/view/29515 ▶ 그레일, ‘암 조기진단’ FDA자문위 "내달 23일 개최" https://www.biospectator.com/news/view/29506 ▶ 비원, 레볼루션 ‘RAS(ON) 4종’ 병용개발·亞권리 “L/I” https://www.biospect…
11 Aug 2026, 09:04 UTC558 viewsread 12 August 2026
루닛, 상반기 매출 458억 "전년比 23% 증가" 영업손실 289억, 전년比 31% 감소..2분기 매출 218억, 전년比 22.5% 증가 https://m.biospectator.com/view/news_view.php?varAtcId=29524
11 Aug 2026, 06:09 UTC≈5,570 viewsread 12 August 2026
재즈 파마슈티컬(Jazz Pharmaceuticals)이 뇌전증(epilepsy) 포트폴리오를 강화하는 전략으로 액티오 바이오사이언스(Actio Biosciences)를 최대 13억2000만달러 규모에 인수하네요. 이번 인수는 KCNT1(K+ channel subfamily T member 1) 저해제 ‘ABS-1230’을 확보하기 위한 것으로, 해당 에셋과 관련없는 나머지 자산은 새로 설립되는 스핀오프 회사(‘SpinCo’)로 이전됩니다. ABS-1230은 KCNT1 관련 뇌전증 치료제로 개발중인 임상단계의 저분자화합물인데요. 액티오에 따르면 ABS-1230은 KCNT1 뇌전증을 앓는 소아 환자를 대상으로 한 개념입증(PoC) 임상에서 의미있는 발작감소 효과를 보였습니다. 르네 갈라(Renee Gala) 재즈 사장 겸 CEO는 "ABS-…
11 Aug 2026, 04:51 UTC602 viewsread 12 August 2026
삼진제약, 컨슈머헬스 총괄본부장에 김대현 상무 영입 ‘게보린’, ‘안정액’ 등 주요 제품 경쟁력 강화 https://www.biospectator.com/news/view/29522
11 Aug 2026, 04:50 UTC593 viewsread 12 August 2026
비원메디슨(BeOne Medicines)은 레볼루션메디슨(Revolution Medicines)으로부터 RAS(ON) 저해제 약물들의 아시아 특정 지역에서의 임상개발 및 판매 라이선스를 사들였네요. 이번 계약을 통해 비원은 레볼루션의 pan-RAS(ON) 저해제 ‘다락손라십(daracsonlasib, RMC-6236)’, RAS(ON) G12D 저해제 ‘졸돈라십(zoldonlasib, RMC-9805)’, RAS(ON) G12C 저해제 ‘엘리론라십(elironrasib, RMC-6291)’, 그리고 RAS(ON) G12V 저해제 ‘RMC-5127’ 4가지 약물에 대한 병용임상 개발 등의 권리를 갖게 됩니다. 레볼루션은 RAS 저해제 분야에서 선도적인 성과를 보여왔으며, 특히 지난 5월 미국 임상종양학회(ASCO 2026)에서 발표한 pan…
11 Aug 2026, 01:37 UTC≈3,140 viewsread 12 August 2026
미국 식품의약국(FDA) 의료기기 자문위원회(Medical Devices Advisory Committee)가 오는 9월 23일 그레일(GRAIL)의 다중암 조기진단(multi-cancer early detection, MCED) 제품 ‘갤러리(Galleri®)’의 시판전승인(PMA) 신청서를 논의하기 위한 자문위를 개최한다고 그레일이 지난 7일(현지시간) 밝혔습니다. https://www.biospectator.com/news/view/29506
11 Aug 2026, 01:31 UTC531 viewsread 12 August 2026
희귀안구질환을 적응증으로 비타민A 대체 약물 ‘길데우레티놀(gildeuretinol, ALK-001)’을 개발하고 있는 알케우스 파마슈티컬(Alkeus Pharmaceuticals)이 총 8억달러 규모로 타르수스 파마슈티컬(Tarsus Pharmaceuticals)에 피인수됩니다. 길데우레티놀은 화학적으로 변형된 비타민A이며, 자연형태의 비타민A를 대체해 독성 이량체(vitaminA dimers) 형성을 방지하는 기전인데요. 1일1회 경구복용방식으로 현재 스타가르트병(Stargart disease)을 적응증으로 하는 임상3상에서 평가중입니다. 타르수스는 이번 알케우스 인수로 망막 분야에서의 입지를 강화하고, 지난달 인수한 또다른 안과전문 개발 기업 아이레닉스메디컬(iRenix Medical)을 통해 확보한 역량을 보완하며, 안과분야를 선도…
11 Aug 2026, 00:19 UTC517 viewsread 12 August 2026
진균(fungi) 유전체 기반 플랫폼을 활용하는 라이프마인 테라퓨틱스(LifeMine Therapeutics)가 2억6300만달러의 투자를 유치했네요. 이번 자금조달은 시리즈D 7500만달러와 시리즈E 1억8800만달러로 구성됐습니다. 앞서 지난 2022년 라이프마인이 시리즈C로 1억7500만달러를 유치했을 당시 GSK(GlaxoSmithKline), 구글벤처스(GV), 아치벤처파트너스(Arch Venture Partners) 등 7곳이 투자에 참여했었는데요. 회사는 이번 시리즈D에도 기존투자자가 참여했으며, 신규 투자자로 로라캐피탈파트너스(LoLa Capital Partners)가 참여했다고 설명했습니다. 또한 시리즈E에는 밀키웨이 인베스트먼트(Milky Way Investments) 가 리드했으며, 기존 투자자인 GSK, 구글벤처스, …
10 Aug 2026, 22:10 UTC636 viewsread 12 August 2026
#바이오스펙테이터 #전일(8/10, MON) #전체기사 ▶ 다케다, 'OX2R 작용제' 美승인..”기면증 치료 재정의” https://www.biospectator.com/news/view/29491 ▶ 브레이브하트, 나스닥 IPO 3.82억弗.."HCM 3상 개발" https://www.biospectator.com/news/view/29489 ▶ 올릭스, CDO에 'GSK 출신' 민지영 수석부사장 영입 https://www.biospectator.com/news/view/29507 ▶ 악투러스, CSL과 '자가증폭 mRNA' 백신개발 "계약해지" https://www.biospectator.com/news/view/29502 ▶ 지씨셀, 손주희 사업개발실장 영입 https://www.biospectator.com/news/view…
Showing the 12 most recent of 51 posts we hold for @biospectatorT. View and reaction counts are the latest single reading for each post, not a live figure, and a recent post is still accumulating both. A view count marked ≈ was rounded by Telegram before we ever saw it — t.me prints views in full below 1,000 and to three significant figures above, so ≈1,200,000 means somewhere between 1,150,000 and 1,249,999. Unmarked counts are exact. Text is reproduced from the public post preview and truncated for length.
Citation-graph rank
Citation-graph rank — 351,233 of 1,160,990entries in the measured graph. A weighted position computed from the forward and mention edges below — republished posts weigh more than named mentions — and recomputed periodically, over the whole graph. Published only as this ordinal position, never as a score: a position is a fact, and a score printed beside one channel’s name would read as a verdict this register does not make. The two counts beneath stay separate for the same reason mentions are never summed with forwards anywhere else on this page — a named-by count costs nothing to manufacture. The top 100 by this measure, or how it is computed.
Forward network
Republished by
Channels on the register that have forwarded this channel's posts into their own feed.
[IV리서치] 제약/바이오
@buy_oh · 3182 posts[IV Research]
@IVResearch · 2,4742 postsMJ의 Bio & Healthcare
@BarbarianBHC · 4,9761 post간절한 투자스터디카페
@desperatestudycafe · 18,8841 postBUY(!)BUY(!)바이오🤡DS 제약/바이오 김민정
@mnJeong_BIO · 7,6401 post@오스코텍 IR/PR 공식 채널
@oscotecinc · 5321 post제약/바이오/미용 원리버 Oneriver
@pharmbiohana · 29,8791 post
@buy_oh · 3182 posts[IV Research]
@IVResearch · 2,4742 postsMJ의 Bio & Healthcare
@BarbarianBHC · 4,9761 post간절한 투자스터디카페
@desperatestudycafe · 18,8841 postBUY(!)BUY(!)바이오🤡DS 제약/바이오 김민정
@mnJeong_BIO · 7,6401 post@오스코텍 IR/PR 공식 채널
@oscotecinc · 5321 post제약/바이오/미용 원리버 Oneriver
@pharmbiohana · 29,8791 post
Built only from forwarded posts we have actually read, on both sides. Coverage is early and deliberately incomplete: a missing link means we have not read the post that would prove it, never that the relationship does not exist. Counts are distinct forwarded posts observed, so they only ever go up as we read more.
Cite this entry
A live page changes as we take new readings, so a citation should name the measurement it is based on, not just the URL. The line below cites the subscriber count as measured 10 August 2026 — this entry's latest reading, not the date you are reading this.
“바이오스펙테이터” (@biospectatorT), 5,878 subscribers as measured 10 August 2026. Telegram Register, tgregister.com/channel/biospectatorT.
Full measurement history, CC BY 4.0. Every reading this register holds for this entry, not just the latest one, as a dated, downloadable record: CSV · JSON. Free to use with attribution to tgregister.com. Each file carries its own generation timestamp, which is the figure to cite for exactly when the data was retrieved.